Latest news with #NASDAQ
Yahoo
25 minutes ago
- Business
- Yahoo
How To Earn $500 A Month From PepsiCo Stock Ahead Of Q2 Earnings
PepsiCo, Inc. (NASDAQ:PEP) will release earnings results for the second quarter, before the opening bell on Thursday, July 17. Analysts expect the soft drink and snack company to report quarterly earnings at $2.03 per share. It reported $2.28 per share in the previous year. PepsiCo is also projected to report quarterly revenue of $22.3 billion. Compare that to $22.5 billion a year earlier, according to data from Benzinga Pro. On Tuesday, Barclays analyst Lauren Lieberman maintained PepsiCo with an Equal-Weight rating and lowered the price target from $135 to $132. With the recent buzz around PepsiCo, some investors may be eyeing potential gains from the company's dividends too. Currently, PepsiCo offers an annual dividend yield of 4.31%. That's a quarterly dividend amount of $1.42 per share ($5.69 a year). To figure out how to earn $500 monthly from PepsiCo, we start with the yearly target of $6,000 ($500 x 12 months). Next, we take this amount and divide it by PepsiCo's $5.69 dividend: $6,000 / $5.69 = 1,054 shares. So, an investor would need to own approximately $141,036 worth of PepsiCo, or 1,054 shares to generate a monthly dividend income of $500. Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $5.69 = 211 shares, or $28,234 to generate a monthly dividend income of $100. View more earnings on PEP Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time. The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change. For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60). Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40). Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease. PEP Price Action: Shares of PepsiCo fell by 1.3% to close at $133.81 on More: Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? PEPSICO (PEP): Free Stock Analysis Report This article How To Earn $500 A Month From PepsiCo Stock Ahead Of Q2 Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Business
- Yahoo
Qualigen Granted New Patents Covering 25 Countries
CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the 'Company' or 'Qualigen') is announcing an update on patents granted in the first six months of 2025. The patent is Titled 'Substitued Naphthalene Diimides and Their Use.' The patent is for the drug, which was developed by Professor Stephen Neidle and his team at the University College of London, and is licensed by Qualigen Therapeutics, QN-302. These patents cover the product and their methods of manufacturing. Through validations and process across Europe these patents were granted and cover the majority of the Euoprean population. In total over 20 countries in Europe have patent coverage for QN-302. Qualigen has also been granted similar patent coverage in India, China and Russia. The expiration on these patents extends into 2040. 'Having the patents granted covering so much of the world's population strengthens our position as a drug development company. By assuring such strong coverage will allow us to continue bringing QN-302 to market and treating patients suffering from Pancreatic and Gastrointestinal Cancer.', stated Kevin Richardson II, CEO of Qualigen. Qualigen will provide periodic updates on new patents granted, as there are a number which have been published and others which are pending. About Qualigen Therapeutics, Inc. For more information about Qualigen Therapeutics, Inc., please visit Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release. Forward-Looking Statements This news release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'anticipates,' 'estimates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'likely,' 'will,' 'should' or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company's forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company's ability to regain compliance with Nasdaq's continued listing requirements, including the Company's ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company's shares from The Nasdaq Capital Market due to its failure to comply with the Nasdaq's continued listing requirement, or its alternatives, or otherwise in the future, and the other risks set forth in the Company's filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Contact: Investor Relationsir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Business
- Yahoo
NETGEAR Schedules Second Quarter 2025 Results Conference Call
SAN JOSE, Calif., July 16, 2025--(BUSINESS WIRE)--NETGEAR®, Inc. (NASDAQ: NTGR), a global leader in intelligent networking solutions designed to power extraordinary experiences, today announced that it will hold a conference call with investors and analysts on Wednesday, July 30 at 5:00 p.m. ET (2:00 p.m. PT) to discuss the Company's second quarter 2025 results and third quarter 2025 business outlook. The news release announcing the second quarter 2025 results will be disseminated on July 30, 2025 after the market closes. The toll-free dial-in number for the live audio call beginning at 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, July 30, 2025 is (888) 660-6392. The international dial-in number for the live audio call is (929) 203-0899. The conference ID for the call is 1030183. A live webcast of the conference call will be available on NETGEAR's Investor Relations website at A replay of the call will be available via the web at About NETGEAR, Inc. Founded in 1996 and headquartered in the USA, NETGEAR® (NASDAQ: NTGR) is a global leader in innovative networking technologies for businesses, homes, and service providers. NETGEAR delivers a wide range of award-winning, intelligent solutions designed to unleash the full potential of connectivity and power extraordinary experiences. For businesses, NETGEAR offers reliable, easy-to-use, high-performance networking solutions, including switches, routers, access points, software, and AV over IP technologies, tailored to meet the diverse needs of small and medium enterprises. NETGEAR's consumer products deliver advanced connectivity, powerful performance, and enhanced security features right out of the box, designed to help keep families safe online, whether at home or on the go. More information is available from the NETGEAR Press Room or by calling (408) 907-8000. Connect with NETGEAR: Facebook, Instagram and the NETGEAR blog at © 2025 NETGEAR, Inc. NETGEAR and the NETGEAR logo are trademarks or registered trademarks of NETGEAR, Inc. and its affiliates in the United States and/or other countries. Other brand and product names are trademarks or registered trademarks of their respective holders. The information contained herein is subject to change without notice. NETGEAR shall not be liable for technical or editorial errors or omissions contained herein. All rights reserved. Source: NETGEAR-F View source version on Contacts NETGEAR Investor RelationsErik Bylininvestors@
Yahoo
25 minutes ago
- Business
- Yahoo
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
The Company to host an earnings conference call via webcast AUSTIN, Texas, July 16, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Tuesday, July 29th, 2025, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at ***Participant Dial-In Details*** Joining by PhoneUSA / International Toll +1 (646) 307-1963USA - Toll-Free (800) 715-9871Participants call one of the allocated dial-in numbers and advise the Operator of either the Conference ID 3224490 or Conference Name. Webcast Attendee URLhttps:// Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. Anyone listening to the call is encouraged to read the company's periodic reports available on the company's profile at and including the discussion of risk factors and historical results of operations and financial condition in those reports. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@ Sign in to access your portfolio
Business Wire
26 minutes ago
- Business
- Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Tuesday, July 29th, 2025, at 10:30AM ET. The conference call will be webcast live and available for replay via a link provided in the Events section of the Company's IR pages at ***Participant Dial-In Details*** Joining by Phone USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Participants call one of the allocated dial-in numbers and advise the Operator of either the Conference ID 3224490 or Conference Name. Webcast Attendee URL Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. Anyone listening to the call is encouraged to read the company's periodic reports available on the company's profile at and including the discussion of risk factors and historical results of operations and financial condition in those reports. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology.
